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Review: short acting methylphenidate has short term
efficacy in children and adolescents with attention
deficit disorder
Schachter HM,Pham B,King J, et al.How efficacious and safe is short›acting methylphenidate for the treatment of
attention›deficit disorder in children and adolescents? A meta›analysis. CMAJ 2001 Nov 27;165:1475–88.
QUESTION: What is the efficacy and safety of short acting methylphenidate for
attention deficit disorder (ADD) in children and adolescents?
Data sources
Studies in any language published between 1981 and
1999 were identified by searching Medline, EMBASE/
Excerpta Medica, PsycINFO, ERIC, CINAHL,
HEALTHStar, Biological Abstracts, Current Contents,
Dissertation Abstracts, Cochrane Library Trials Register,
and Current Controlled Trials; reviewing bibliographies
of included studies and pertinent reviews; and reviewing
the files of content experts.
Study selection
Randomised placebo controlled trials were included if
they assessed the effects of short acting methylphenidate
in children<18 years of age with a primary diagnosis of
ADD (based on a systematic and reproducible method).
Exclusion criteria were n of 1 studies, participants with
conditions that required specialised school and/or
home environments (eg, mental retardation or autism),
or participants receiving stimulants other than methyl›
phenidate.
Data extraction
Data were extracted on characteristics of the trial, popu›
lation, and intervention; behavioural efficacy (eg, pri›
mary outcomes of teacher and parent versions of the
hyperactivity index [HI]); and adverse events. Quality of
individual studies was assessed using the 3 item Jadad
scale (randomisation, blinding, and follow up) and an
index of concealment of treatment allocation.
Main results
62 trials (n=2897) met the selection criteria. Mean sam›
ple size was 47. Median age of participants was 8.7 years
(52 trials) and median percentage of boys was 88% (59
trials). 45 trials included participants with a homogene›
ous primary diagnosis of attention deficit hyperactivity
disorder or ADD with hyperactivity (ADHD). Mean
length of intervention was 3.3 weeks.
Children who received methylphenidate had reduced
scores on both teacher and parent reported HI
compared with those who received placebo (table).
Similar results (albeit of variable and smaller magni›
tudes) were found for teacher reported clinical response,
global indices, core features, and key externalising
features; attention and emotional lability did not differ
between groups. Variable and weaker results were found
for parent reported clinical response, global indices,
core features, and key externalising features; inattention,
hyperactivity/impulsivity, and oppositional defiant be›
haviour did not differ between groups. Children who
received methylphenidate had higher parent/self rat›
ings of decreased appetite, insomnia, headache, and
stomachache (table).
Conclusions
Short acting methylphenidate reduces some core and
related clinical manifestations of attention deficit disor›
der in children and adolescents in the short term, but is
associated with increased adverse events. No long term
studies were found.
Methylphenidate v placebo in children and adolescents with attention deficit disorder*
Outcomes Standardised mean difference (95% CI)
Hyperactivity index (teacher reported) 0.78 (0.64 to 0.91)
Hyperactivity index (parent reported) 0.54 (0.40 to 0.67)
Parent/self reported adverse events Methylphenidate Placebo NNH (CI)
Decreased appetite 45% 14% 4 (3 to 6)
Insomnia 48% 31% 6 (4 to 13)
Headache 18% 13% 17 (10 to 72)
Stomachache 24% 15% 12 (6 to 84)
*Abbreviations defined in glossary; NNH and CI calculated from absolute risk difference data in article.
COMMENTARY
The meta›analysis by Schachter et al supports a robust body of literature showing the
efficacy of methylphenidate for the acute treatment of ADHD disorders in children and
adolescents. Given the continuing suspicion with which the diagnosis is viewed by some
elements of the lay public, the results of this study are welcome.
The analysis identifies problems with the extant literature, such as generally small
study sample sizes that include a preponderance of boys, the short duration of most
studies, and outcome measures that may confound ADHD with externalising comorbid
behaviours. Because of these limitations, the authors suggest that broad generalisations
about the usefulness of methylphenidate should probably be avoided.
The results raise several issues. Firstly, the moderate effect size of 0.54 for parent
reported hyperactivity appears less robust than in previous ADHD studies, which report
overall effect sizes of 0.8–1.1.1 2 One explanation may be that 52 of the reviewed studies
(84%) used either once daily or twice daily dosing strategies. Immediate release (IR)
methylphenidate may wear off before the child returns home after school, resulting in
the larger effect sizes reported by teachers. The current standard of care is 3 daily doses
to help the child in the after school hours. Secondly, the results show the need for stud›
ies of longer duration. To date, 2 controlled studies have reported stimulant benefits
continuing for up to 14 months.2 3 Thirdly, although children treated with methylpheni›
date have higher rates of medication induced side effects, it is important to compare
these risks with the risks of untreated ADHD. Clearly, untreated ADHD has far greater
detrimental effects on the child’s development than the side effects of stimulants. This
must be appropriately framed for the child’s parents when clinicians discuss potential
stimulant side effects. Finally, the role of IR stimulants will diminish given that the
standard treatment is changing to long acting, once daily stimulants.
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